An update on the neurologic applications of botulinum toxins
- PMID: 20567945
- DOI: 10.1007/s11910-010-0129-z
An update on the neurologic applications of botulinum toxins
Abstract
Initially used to treat strabismus in the 1970s, botulinum toxin now has more than a hundred possible medical applications. Its utility in neurologic conditions has largely involved treating movement disorders (particularly dystonia and conditions with muscle hyperactivity), although practically any hyperkinetic movement disorder may be relieved by botulinum toxin, including hemifacial spasm, tremor, tics, myoclonus, and spasticity. Although initially thought to inhibit acetylcholine release only at the neuromuscular junction, botulinum toxins are now recognized to inhibit acetylcholine release at autonomic cholinergic nerve terminals, as well as peripheral release of neurotransmitters involved in pain regulation. Thus, their use in neurology has been expanded to include headache and other pain syndromes, as well as hypersecretory disorders. This article highlights some of the common neurologic conditions currently improved by botulinum toxins and reviews the scientific evidence from research studies and clinical experience with these conditions.
Similar articles
-
Botulinum toxin in movement disorders.Semin Neurol. 2007 Apr;27(2):183-94. doi: 10.1055/s-2007-971171. Semin Neurol. 2007. PMID: 17390263 Review.
-
Current clinical applications of botulinum toxin.Curr Pharm Des. 2009;15(31):3671-80. doi: 10.2174/138161209789271843. Curr Pharm Des. 2009. PMID: 19925419 Review.
-
Therapeutic uses of botulinum toxin.Am Fam Physician. 1997 Feb 1;55(2):541-5, 548. Am Fam Physician. 1997. PMID: 9054223 Review.
-
The current use of botulinum toxin.J Clin Neurosci. 2000 Sep;7(5):389-94. doi: 10.1054/jocn.2000.0684. J Clin Neurosci. 2000. PMID: 10942658 Review.
-
Botulinum toxin: clinical use.Parkinsonism Relat Disord. 2006 Sep;12(6):331-55. doi: 10.1016/j.parkreldis.2006.06.002. Epub 2006 Jul 25. Parkinsonism Relat Disord. 2006. PMID: 16870487 Review.
Cited by
-
Structural Features of Clostridium botulinum Neurotoxin Subtype A2 Cell Binding Domain.Toxins (Basel). 2022 May 19;14(5):356. doi: 10.3390/toxins14050356. Toxins (Basel). 2022. PMID: 35622602 Free PMC article.
-
Insights into the mechanism of onabotulinumtoxinA in chronic migraine.Headache. 2011 Nov-Dec;51(10):1573-7. doi: 10.1111/j.1526-4610.2011.02022.x. Headache. 2011. PMID: 22082429 Free PMC article. Review.
-
Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.Infect Immun. 2013 Oct;81(10):3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5. Infect Immun. 2013. PMID: 23918782 Free PMC article.
-
Endomicroscopy and electromyography of neuromuscular junctions in situ.Ann Clin Transl Neurol. 2014 Nov;1(11):867-83. doi: 10.1002/acn3.124. Epub 2014 Oct 10. Ann Clin Transl Neurol. 2014. PMID: 25540801 Free PMC article.
-
Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective.Front Psychiatry. 2021 Apr 23;12:584416. doi: 10.3389/fpsyt.2021.584416. eCollection 2021. Front Psychiatry. 2021. PMID: 33967844 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical